by Michael Boyd | Jul 25, 2023 | Publications
A group promoting the importance of non-monotonic dose responses for endocrine disruptors contend that scoring systems giving primacy to GLP are biased against non-GLP studies from the literature and are merely record-keeping exercises to prevent fraudulent reporting...
by Michael Boyd | Jul 25, 2023 | Publications
There is a recognized need to improve the application of epidemiologic data in human health risk assessment especially for understanding and characterizing risks from environmental and occupational exposures. Although there is uncertainty associated with the results...
by Michael Boyd | Jul 25, 2023 | Publications
To place endocrine screening results in the context of potency and human exposure, we propose a method that entails (1) calculating a benchmark dose for a response measured in an endocrine screen; (2) estimating the human urinary concentration (biomonitoring...
by Michael Boyd | Jul 25, 2023 | Publications
In 2009, companies began screening compounds using the US Environmental Protection Agency’s Endocrine Disruptor Screening Program (EDSP). EDSP has two tiers: Tier 1 includes 11 assays to identify compounds with potential endocrine activity. This article...
by Michael Boyd | Jul 25, 2023 | Publications
A wide variety of potentially endocrine-relevant endpoints were identified for mollusks, fish, amphibians, birds, and mammals, although the strength of the relationship between test endpoints and population-level effects was often uncertain. Furthermore, testing alone...
Recent Comments